AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

Ken Griffin's 546% AbbVie Bet Is History. Whether the Dividend King ...

Dividend AI-generated analysis

πŸ“ˆ Ken Griffin's Citadel increased its AbbVie stake by 546% in Q2 2026, adding 2.7 million shares at prices around $200 before the stock rose to $285.

πŸ“‰ The company maintains a 50+ year dividend growth streak with a current yield of 2.4% based on the $1.73 quarterly payout.

πŸ’Š Skyrizi revenue grew 24.4% to $5.5 billion and Rinvoq rose 24.5% to $2.5 billion in Q2, offsetting Humira's decline.

⚠️ Free cash flow coverage of dividends has weakened to 1.5x as the payout ratio increased from 41% to 65% between fiscal 2022 and 2025.

πŸ’° Net debt stands at $64 billion with a leverage ratio of 2.26x EBITDA, funded by acquisitions like the pending $10.9 billion Apogee Therapeutics deal.

πŸ“‰ AbbVie cut its 2026 adjusted EPS guidance to a midpoint of $13.86 due to $1.25 billion in acquired IPR&D and milestone expenses.

πŸ›οΈ The stock trades at a forward P/E of roughly 20x, which analysts consider a fair valuation for a high-quality compounder rather than a bargain.

πŸ”¬ The pipeline includes approximately 90 clinical programs, with two-thirds in mid- or late-stage development, offering potential upside if new indications succeed.

Bullish Signals
  • AbbVie maintains an impressive 50+ year dividend growth streak, recently hiking the quarterly payout by 5.5% to $1.73.
  • Key immunology engines Skyrizi and Rinvoq combined generated over $8 billion in Q2 revenue with double-digit growth rates.
  • The company has successfully transitioned past the Humira cliff, with earnings inflecting from their trough as new drugs compound.
  • The stock trades at a forward P/E of roughly 20x, reflecting fair valuation for a quality compounder with high single-digit to low double-digit earnings growth.
Risk Factors
  • Free cash flow coverage of dividends has weakened to 1.5x as the payout ratio rose from 41% in fiscal 2022 to 65% in fiscal 2025.
  • The company carries a $64 billion net debt load with 2.26x EBITDA leverage, funded largely by acquisitions and high IPR&D expenses.
  • The pending acquisition of Apogee Therapeutics for $10.9 billion is expected to trim 2026 EPS by approximately $0.14.
Full Analysis
AbbVie (ABBV) recently saw a significant increase in stake by Citadel's Ken Griffin, who added 2.7 million shares in Q2 2026 at prices in the low $200s, representing a 546% jump in his position. However, the article clarifies that this investment thesis is now outdated as the stock has appreciated to approximately $285 per share, moving past analyst targets set in August. The company maintains its status as a Dividend King with a 50+ year streak of dividend increases, currently offering a 2.4% yield at the current price. This growth is driven by strong performance from its key immunology drugs, Skyrizi and Rinvoq, which combined generated over $8 billion in revenue in Q2 despite the continued decline of Humira. Despite the robust dividend history, financial metrics indicate a tightening cushion with free cash flow coverage dropping to 1.5x and net debt reaching $64 billion. The company recently cut its 2026 EPS guidance due to high acquisition-related expenses, signaling that growth is being funded by significant borrowing rather than organic cash generation. Analysts view the current valuation as fair rather than a bargain, with a forward P/E of roughly 20x reflecting a quality compounder at a reasonable price. The investment case remains valid for long-term income investors willing to accept a fair entry point and wait for growth engines to compound value, though the specific discount sought by previous investors is no longer available.